Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients.

Cells · 2022 · PMC8773801 · PMID 35053324

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendp = 0.08so close (0.05 < p ≤ 0.1)

Respective MIF values at baseline, day 90 and day 150 showed a trend towards a down-regulation of HLA-DR expression, being 32116 (15222–39935), 21875 (3174–38665), and 26188 (18563–48282) respectively ( p = 0.08).

also in 53,322 other papers

a decreasing trendno p-value reported

On day 90, all 6 patients showed a decreasing trend of PBMC TID as compared to day −30, but a favorable outcome was seen only in 2 out of 6 patients after RLT administration, throughout the course of the study ( Figure 1 ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.